©2022 Stanford Medicine
A Study of Esomeprazole in Children With Autism
Trial ID: NCT03866668
Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication and the presence of repetitive/stereotyped behaviors. The objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12 week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of age to participate.
An Open-Label Pilot Study of Esomeprazole in Children With Autism
- outpatients 2 to 6 years of age;
- males and females who are physically healthy;
- diagnosis of autism spectrum disorder based on clinical evaluation and DSM-5 criteria,
and confirmed using the Autism Diagnostic Interview-Revised, and the Autism Diagnostic
- care provider who could reliably bring subject to clinic visits, could provide
trustworthy ratings, and interacted with subject on a regular basis;
- ability of subject to swallow the compound;
- stable concomitant medications for at least 2 weeks (4 weeks if patient took
- no planned changes in psychosocial interventions during the open-label trial.
- DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not
- prior adequate trial of Esomeprazole;
- active medical problems such as unstable seizures, or significant physical illness
(e.g., serious liver or renal pathology).
School of Medicine
300 Pasteur Drive
Stanford, CA 94305